These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24062394)

  • 1. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases.
    Soliman H; Ringash J; Jiang H; Singh K; Kim J; Dinniwell R; Brade A; Wong R; Brierley J; Cummings B; Zimmermann C; Dawson LA
    J Clin Oncol; 2013 Nov; 31(31):3980-6. PubMed ID: 24062394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Klein J; Dawson LA; Jiang H; Kim J; Dinniwell R; Brierley J; Wong R; Lockwood G; Ringash J
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):16-25. PubMed ID: 26279020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical assessment of palliative radiotherapy for pancreatic cancer.
    Tian Q; Zhang F; Wang Y
    Cancer Radiother; 2018 Dec; 22(8):778-783. PubMed ID: 30401617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study.
    Dawson LA; Ringash J; Fairchild A; Stos P; Dennis K; Mahmud A; Stuckless TL; Vincent F; Roberge D; Follwell M; Wong RKW; Jonker DJ; Knox JJ; Zimmermann C; Wong P; Barry AS; Gaudet M; Wong RKS; Purdie TG; Tu D; O'Callaghan CJ
    Lancet Oncol; 2024 Oct; 25(10):1337-1346. PubMed ID: 39245060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
    Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
    J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC).
    Yeung CSY; Chiang CL; Wong NSM; Ha SK; Tsang KS; Ho CHM; Wang B; Lee VWY; Chan MKH; Lee FAS
    Sci Rep; 2020 Jan; 10(1):1254. PubMed ID: 31988376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22.
    Zeng L; Chow E; Bedard G; Zhang L; Fairchild A; Vassiliou V; Alm El-Din MA; Jesus-Garcia R; Kumar A; Forges F; Tseng LM; Hou MF; Chie WC; Bottomley A
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e337-42. PubMed ID: 22763028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases.
    Caissie A; Zeng L; Nguyen J; Zhang L; Jon F; Dennis K; Holden L; Culleton S; Koo K; Tsao M; Barnes E; Danjoux C; Sahgal A; Simmons C; Chow E
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):125-33. PubMed ID: 21917431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial.
    Tey J; Zheng H; Soon YY; Leong CN; Koh WY; Lim K; So JBY; Shabbir A; Tham IWK; Lu J
    Cancer Med; 2019 Apr; 8(4):1447-1458. PubMed ID: 30790469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative (131)I-lipiodol therapy.
    Brans B; Lambert B; De Beule E; De Winter F; Van Belle S; Van Vlierberghe H; de Hemptinne B; Dierckx RA
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1374-9. PubMed ID: 12271421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Organization for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30 version 3.0 Turkish) in cancer patients receiving palliative radiotherapy.
    Hiçsönmez A; Köse K; Andrieu MN; Güney Y; Kurtman C
    Eur J Cancer Care (Engl); 2007 May; 16(3):251-7. PubMed ID: 17508945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom clusters in patients with cancer with metastatic bone pain.
    Hadi S; Fan G; Hird AE; Kirou-Mauro A; Filipczak LA; Chow E
    J Palliat Med; 2008 May; 11(4):591-600. PubMed ID: 18454612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire.
    Pistevou-Gombaki K; Eleftheriadis N; Plataniotis GA; Sofroniadis I; Kouloulias VE
    Palliat Med; 2003 Apr; 17(3):257-62. PubMed ID: 12725479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
    Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma.
    Sandroussi C; Dawson LA; Lee M; Guindi M; Fischer S; Ghanekar A; Cattral MS; McGilvray ID; Levy GA; Renner E; Greig PD; Grant DR
    Transpl Int; 2010 Mar; 23(3):299-306. PubMed ID: 19843294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy.
    Schultheis K; Hofheinz RD; Gencer D; Blunk JA; Benrath J
    Onkologie; 2013; 36(1-2):33-7. PubMed ID: 23429329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.
    Blazeby JM; Currie E; Zee BC; Chie WC; Poon RT; Garden OJ;
    Eur J Cancer; 2004 Nov; 40(16):2439-44. PubMed ID: 15519517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity and reliability of the Swedish version of the Memorial Symptom Assessment Scale (MSAS): an instrument for the evaluation of symptom prevalence, characteristics, and distress.
    Browall M; Kenne Sarenmalm E; Nasic S; Wengström Y; Gaston-Johansson F
    J Pain Symptom Manage; 2013 Jul; 46(1):131-41. PubMed ID: 23195392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life after palliative treatment for oesophageal carcinoma -- a prospective comparison between stent placement and single dose brachytherapy.
    Homs MY; Essink-Bot ML; Borsboom GJ; Steyerberg EW; Siersema PD;
    Eur J Cancer; 2004 Aug; 40(12):1862-71. PubMed ID: 15288288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.